KAIST 생명과학과동창회
  • News & Events
  • News

News

Antibiotic tolerance study paves way for new treatments


A new study identifies a mechanism that makes bacteria tolerant to penicillin and related antibiotics, findings that could lead to new therapies that boost the effectiveness of these treatments.


Antibiotic tolerance is the ability of bacteria to survive exposure to antibiotics, in contrast to antibiotic resistance, when bacteria actually grow in the presence of antibiotics. Tolerant bacteria can lead to infections that persist after treatment and may develop into resistance over time.

The study in mice, “A Multifaceted Cellular Damage Repair and Prevention Pathway Promotes High Level Tolerance to Beta-lactam Antibiotics,” published Feb. 3 in the journal EMBO Reports, reveals how tolerance occurs, thanks to a system that mitigates iron toxicity in bacteria that have been exposed to penicillin.


“We’re hoping we can design a drug or develop antibiotic adjuvants that would then basically kill off these tolerant cells,” said senior author Tobias Dörr, assistant professor of microbiology in the Weill Institute for Cell and Molecular Biology in the College of Agriculture and Life Sciences.


Co-authors included Ilana Brito, the Mong Family Sesquicentennial Faculty Scholar and assistant professor in the Meinig School of Biomedical Engineering in the College of Engineering, and Lars Westblade, associate professor of pathology and laboratory medicine at Weill Cornell Medicine.


Some bacteria, including the model bacterium used in the study, Vibrio cholerae, which causes cholera in humans, are remarkably tolerant to penicillin and related antibiotics, known as beta lactam antibiotics. It has been known for a long time that beta-lactam antibiotics break down bacterial cell walls, but how bacteria survive loss of their cell walls was poorly understood.


In the study, the researchers developed a V. cholerae mutant that lacked a two-component damage repair response system that controls a gene network encoding diverse functions. Without the system, known as VxrAB, when the cell wall is damaged by antibiotics, the transfer of electrons across the cell membrane goes awry, leading to electrons ending up on the wrong molecules. This misdirection causes hydrogen peroxide to accumulate in the cell, which changes the oxidation state of cellular iron and disrupts signals for the cell to tell how much iron it has.   


In the presence of hydrogen peroxide, the mutant bacteria cannot sense how much iron has been acquired, and it behaves as if it is iron-starved and seeks to acquire more iron. Left unchecked, these circumstances cause iron toxicity, which will kill the cell, according to the experiments the researchers conducted. In further tests with mutant V. cholerae bacteria, both in test tubes and in mice, the researchers showed that reducing the influx of iron increased the bacteria’s tolerance to beta lactams.


Fortunately for normal V. cholerae, exposure to antibiotics and the breakdown of the cell’s walls activate the VxrAB system, which works to repair cell walls and downregulates iron uptake systems, and thereby creates antibiotic tolerance. More study is needed to understand what triggers the VxrAB system in the presence of beta-lactam antibiotics.


The research opens the door for developing new drugs that could be combined with antibiotics to exploit oxidative damage and iron influx in tolerant bacteria. In future work, the researchers will search for parallel mechanisms of tolerance in other bacterial pathogens.


Jung-Ho Shin, a postdoctoral researcher in Dörr’s lab, is the paper’s first author. Co-authors include researchers from the Korea Advanced Institute of Science and Technology, the Korea Advanced Institute of Science and Technology, and the Intelligent Synthetic Biology Center in Korea.

The study was funded by the National Research Foundation of Korea and the National Institutes of Health.


https://news.cornell.edu/stories/2021/02/antibiotic-tolerance-study-paves-way-new-treatments

https://www.miragenews.com/antibiotic-tolerance-study-paves-way-for-new-516267/



List of Articles
번호 제목 글쓴이 날짜 조회 수
139 [한겨레] BK21 중간평가: 최우수사업단으로 선정 과사무실 2004.12.09 11520
138 [최길주, 김상규 교수님] 카오스재단 2022 봄 카오스강연 ‘식물행성 (Plant Planet)’ 에서 강연(4/6) 생명과학과 2022.02.22 692
137 [진에딧 이근우 대표] 한국인이 세운 ‘유전자 가위’ 스타트업… 실리콘밸리가 침흘리는 이유 생명과학과 2021.12.20 1095
136 [중앙일보] 생명과학과 박지혜 '로레알 여성생명과학상' 수상 과사무실 2006.06.22 13620
135 [중앙일보] 김재섭 교수 치매 막는 신물질 4종 발견 과사무실 2005.08.08 12195
134 [조원기 교수님] 세포 기능 결정에 핵심 역할 유전자 발현 단백질 찾았다 생명과학과 2021.12.24 798
133 [조선일보] 생명과학과 김정회교수팀...자일리톨 추출 신기술 개발 과사무실 2007.08.29 14159
132 [조선일보] 김재섭 교수 고열에도 뇌손상 막는 유전자 최초 발견 과사무실 2005.01.31 12183
131 [조선일보] AMPK유전자, 암세포 치료에도 이용...정종경 교수팀 과사무실 2007.05.08 12151
130 [조병관 교수님] 한국연구재단, 노화 방지하고 회춘하는 방법 제시 생명과학과 2022.01.13 783
129 [조병관 교수님] 카이스트 조병관 교수팀, 합성생물학 기반 차세대 미생물 대사 조절 밸브 개발 생명과학과 2022.04.15 1034
128 [조병관 교수님] 이산화탄소 흡수해 아세트산 만드는 '친환경 미생물' 5종 발견 생명과학과 2022.06.17 2915
127 [조병관 교수님] 대량의 고농도 일산화탄소를 고부가가치 바이오케미칼로 전환하는 기술 개발 생명과학과 2022.07.15 637
126 [조병관 교수님 연구실] 2022년 안전관리 우수연구실 선정 file 생명과학과 2023.01.27 398
125 [정현정 교수님] 유전자 가위와 약물로 동시에 암을 잡는 신약 개발 생명과학과 2023.08.03 973
124 [정현정 교수님] 유전자 가위로 생체 내 정밀한 유전자 교정에 의한 면역 항암 치료​ 생명과학과 2022.01.18 823
123 [정현정 교수님] 암세포만 골라 유전자 교정 치료하는 신약 개발​ 생명과학과 2024.04.08 449
122 [정인경 교수님] 파킨슨병 발병 3차원 게놈 지도 최초 제시​ 생명과학과 2023.05.08 630
121 [정인경 교수님] 제17회 아산의학상 젊은의학자 부문 수상 생명과학과 2024.03.22 223
120 [정인경 교수님] 인공지능 기반 대장암 3차원 게놈 지도 최초 해독​ 생명과학과 2023.07.25 353
Board Pagination Prev 1 ... 11 12 13 14 15 16 17 18 19 20 ... 22 Next
/ 22